Movement Alert｜Hengrui Medicine Rises 3.17% in Regular Trading, Pipeline Catalysts and Sector Recovery Drive Rebound

Market Focus07-15 11:14

On July 15, Hengrui Medicine (01276.HK) rose 3.17% in regular trading, trading at 60.05 HKD/share, with turnover of approximately HKD 160 million. The stock staged a recovery after declining 3.05% the previous session following the FDA's third Complete Response Letter for its camrelizumab combination therapy BLA.

The rebound was supported by a cluster of pipeline developments. On July 13, the company's HRS-7058 capsule received Breakthrough Therapy Designation from China's CDE for KRAS G12C-mutant locally advanced or metastatic pancreatic cancer. Simultaneously, its SHR-3079 injection secured clinical trial approval for adult systemic lupus erythematosus and rheumatoid arthritis — a first-in-class drug with no similar products approved globally.

The broader pharmaceutical sector provided additional tailwinds, with Asymchem gaining 6.58%, SBP Group up 5.87%, CSPC Pharma up 4.81%, Hansoh Pharma up 4.73%, and Luye Pharma up 4.61%. UBS recently reiterated a Buy rating on Hengrui with an H-share target price of HKD 97.4, citing positive GLP-1 clinical data.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1122411413?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-15 11:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1122411413","market":"us","top_or_hot":-1,"title":"Movement Alert｜Hengrui Medicine Rises 3.17% in Regular Trading, Pipeline Catalysts and Sector Recovery Drive Rebound","media":"Market Focus","content":"<p><p>On July 15, Hengrui Medicine (01276.HK) rose 3.17% in regular trading, trading at 60.05 HKD/share, with turnover of approximately HKD 160 million. The stock staged a recovery after declining 3.05% the previous session following the FDA's third Complete Response Letter for its camrelizumab combination therapy BLA.</p><p>The rebound was supported by a cluster of pipeline developments. On July 13, the company's HRS-7058 capsule received Breakthrough Therapy Designation from China's CDE for KRAS G12C-mutant locally advanced or metastatic pancreatic cancer. Simultaneously, its SHR-3079 injection secured clinical trial approval for adult systemic lupus erythematosus and rheumatoid arthritis — a first-in-class drug with no similar products approved globally.</p><p>The broader pharmaceutical sector provided additional tailwinds, with Asymchem gaining 6.58%, SBP Group up 5.87%, CSPC Pharma up 4.81%, Hansoh Pharma up 4.73%, and Luye Pharma up 4.61%. UBS recently reiterated a Buy rating on Hengrui with an H-share target price of HKD 97.4, citing positive GLP-1 clinical data.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Hengrui Medicine Rises 3.17% in Regular Trading, Pipeline Catalysts and Sector Recovery Drive Rebound</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Hengrui Medicine Rises 3.17% in Regular Trading, Pipeline Catalysts and Sector Recovery Drive Rebound\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-15 11:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 15, Hengrui Medicine (01276.HK) rose 3.17% in regular trading, trading at 60.05 HKD/share, with turnover of approximately HKD 160 million. The stock staged a recovery after declining 3.05% the previous session following the FDA's third Complete Response Letter for its camrelizumab combination therapy BLA.</p><p>The rebound was supported by a cluster of pipeline developments. On July 13, the company's HRS-7058 capsule received Breakthrough Therapy Designation from China's CDE for KRAS G12C-mutant locally advanced or metastatic pancreatic cancer. Simultaneously, its SHR-3079 injection secured clinical trial approval for adult systemic lupus erythematosus and rheumatoid arthritis — a first-in-class drug with no similar products approved globally.</p><p>The broader pharmaceutical sector provided additional tailwinds, with Asymchem gaining 6.58%, SBP Group up 5.87%, CSPC Pharma up 4.81%, Hansoh Pharma up 4.73%, and Luye Pharma up 4.61%. UBS recently reiterated a Buy rating on Hengrui with an H-share target price of HKD 97.4, citing positive GLP-1 clinical data.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01276","symbol_name":"恒瑞医药","start_time":0,"source_url":"","article_id":"1122411413","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1122411413","pubTimestamp":1784085252,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 15, Hengrui Medicine (01276.HK) rose 3.17% in regular trading, trading at 60.05 HKD/share, with turnover of approximately HKD 160 million. The stock staged a recovery after declining 3.05%...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01276":"恒瑞医药"},"translate_title":"动向提醒|恒瑞医药常规交易大涨3.17%，管线催化剂和板块复苏带动反弹","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01276":1},"content_text":"On July 15, Hengrui Medicine (01276.HK) rose 3.17% in regular trading, trading at 60.05 HKD/share, with turnover of approximately HKD 160 million. The stock staged a recovery after declining 3.05% the previous session following the FDA's third Complete Response Letter for its camrelizumab combination therapy BLA.The rebound was supported by a cluster of pipeline developments. On July 13, the company's HRS-7058 capsule received Breakthrough Therapy Designation from China's CDE for KRAS G12C-mutant locally advanced or metastatic pancreatic cancer. Simultaneously, its SHR-3079 injection secured clinical trial approval for adult systemic lupus erythematosus and rheumatoid arthritis — a first-in-class drug with no similar products approved globally.The broader pharmaceutical sector provided additional tailwinds, with Asymchem gaining 6.58%, SBP Group up 5.87%, CSPC Pharma up 4.81%, Hansoh Pharma up 4.73%, and Luye Pharma up 4.61%. UBS recently reiterated a Buy rating on Hengrui with an H-share target price of HKD 97.4, citing positive GLP-1 clinical data.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1122411413","isCrawlerRequest":true}